Nova EYE Medical Ltd
Nova Eye Medical Limited designs, develops, manufactures, markets, and sells surgical devices for the treatment of glaucoma in Australia, the United States, Europe, the Asia Pacific, and internationally. It also engaged in the commercialisation of the subthreshold nano-pulse ophthalmic laser; 2RT, a proprietary laser technology to treat patients in early and intermediate age-related macular degen… Read more
Nova EYE Medical Ltd (EYE) - Net Assets
Latest net assets as of December 2025: AU$15.82 Million AUD
Based on the latest financial reports, Nova EYE Medical Ltd (EYE) has net assets worth AU$15.82 Million AUD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$23.67 Million) and total liabilities (AU$7.85 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | AU$15.82 Million |
| % of Total Assets | 66.84% |
| Annual Growth Rate | 4.67% |
| 5-Year Change | -46.32% |
| 10-Year Change | -60.7% |
| Growth Volatility | 626.79 |
Nova EYE Medical Ltd - Net Assets Trend (1989–2025)
This chart illustrates how Nova EYE Medical Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Nova EYE Medical Ltd (1989–2025)
The table below shows the annual net assets of Nova EYE Medical Ltd from 1989 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | AU$18.97 Million | -11.08% |
| 2024-06-30 | AU$21.33 Million | -8.02% |
| 2023-06-30 | AU$23.19 Million | -23.71% |
| 2022-06-30 | AU$30.40 Million | -13.97% |
| 2021-06-30 | AU$35.34 Million | -64.87% |
| 2020-06-30 | AU$100.59 Million | +46.21% |
| 2019-06-30 | AU$68.80 Million | -6.07% |
| 2018-06-30 | AU$73.24 Million | +28.65% |
| 2017-06-30 | AU$56.93 Million | +17.98% |
| 2016-06-30 | AU$48.26 Million | +21.27% |
| 2015-06-30 | AU$39.79 Million | +7.70% |
| 2014-06-30 | AU$36.95 Million | +19.85% |
| 2013-06-30 | AU$30.83 Million | -3.83% |
| 2012-06-30 | AU$32.06 Million | +5.73% |
| 2011-06-30 | AU$30.32 Million | -8.63% |
| 2010-06-30 | AU$33.19 Million | +10.44% |
| 2009-06-30 | AU$30.05 Million | -37.32% |
| 2008-06-30 | AU$47.94 Million | +10.51% |
| 2007-06-30 | AU$43.38 Million | +23.44% |
| 2006-06-30 | AU$35.14 Million | +21.23% |
| 2005-06-30 | AU$28.99 Million | -4.88% |
| 2004-06-30 | AU$30.48 Million | -0.37% |
| 2003-06-30 | AU$30.59 Million | -0.70% |
| 2002-06-30 | AU$30.81 Million | +3800.18% |
| 2001-06-30 | AU$789.86K | +137.08% |
| 2000-06-30 | AU$333.16K | -35.81% |
| 1999-06-30 | AU$519.02K | -46.56% |
| 1998-06-30 | AU$971.14K | -40.84% |
| 1997-06-30 | AU$1.64 Million | -4.30% |
| 1996-06-30 | AU$1.72 Million | +42.46% |
| 1995-06-30 | AU$1.20 Million | +330.00% |
| 1994-06-30 | AU$280.00K | -42.39% |
| 1993-06-30 | AU$486.00K | -34.41% |
| 1992-06-30 | AU$741.00K | -32.39% |
| 1991-06-30 | AU$1.10 Million | +18.10% |
| 1990-06-30 | AU$928.00K | -74.71% |
| 1989-06-30 | AU$3.67 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Nova EYE Medical Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2380600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | AU$58.94 Million | 310.77% |
| Other Comprehensive Income | AU$-230.00K | -1.21% |
| Total Equity | AU$18.97 Million | 100.00% |
Nova EYE Medical Ltd Competitors by Market Cap
The table below lists competitors of Nova EYE Medical Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Dedicare AB
LSE:0P3K
|
$19.87 Million |
|
Chander Electronics Corp.
TWO:8068
|
$19.87 Million |
|
Prime Financial Group Ltd
AU:PFG
|
$19.88 Million |
|
Shane Global Holding Inc
TW:8482
|
$19.89 Million |
|
Biohit Oyj B
HE:BIOBV
|
$19.87 Million |
|
Buriram Sugar Public Company Limited
BK:BRR
|
$19.86 Million |
|
Elauwit Connection, Inc. Common Stock
NASDAQ:ELWT
|
$19.86 Million |
|
FARMAE S.P.A.
F:U5Y
|
$19.85 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Nova EYE Medical Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 21,330,000 to 18,967,000, a change of -2,363,000 (-11.1%).
- Net loss of 9,059,000 reduced equity.
- Share repurchases of 6,169,000 reduced equity.
- New share issuances of 6,169,000 increased equity.
- Other comprehensive income increased equity by 463,000.
- Other factors increased equity by 6,233,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | AU$-9.06 Million | -47.76% |
| Share Repurchases | AU$6.17 Million | -32.52% |
| Share Issuances | AU$6.17 Million | +32.52% |
| Other Comprehensive Income | AU$463.00K | +2.44% |
| Other Changes | AU$6.23 Million | +32.86% |
| Total Change | AU$- | -11.08% |
Book Value vs Market Value Analysis
This analysis compares Nova EYE Medical Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.79x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 5.38x to 1.79x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1989-06-30 | AU$0.03 | AU$0.14 | x |
| 1990-06-30 | AU$0.01 | AU$0.14 | x |
| 1991-06-30 | AU$1.19 | AU$0.14 | x |
| 1992-06-30 | AU$0.80 | AU$0.14 | x |
| 1993-06-30 | AU$0.51 | AU$0.14 | x |
| 1994-06-30 | AU$0.29 | AU$0.14 | x |
| 1995-06-30 | AU$0.98 | AU$0.14 | x |
| 1996-06-30 | AU$0.91 | AU$0.14 | x |
| 1997-06-30 | AU$0.67 | AU$0.14 | x |
| 1998-06-30 | AU$0.32 | AU$0.14 | x |
| 1999-06-30 | AU$0.17 | AU$0.14 | x |
| 2000-06-30 | AU$0.12 | AU$0.14 | x |
| 2001-06-30 | AU$0.14 | AU$0.14 | x |
| 2002-06-30 | AU$0.50 | AU$0.14 | x |
| 2003-06-30 | AU$0.46 | AU$0.14 | x |
| 2004-06-30 | AU$0.46 | AU$0.14 | x |
| 2005-06-30 | AU$0.44 | AU$0.14 | x |
| 2006-06-30 | AU$0.51 | AU$0.14 | x |
| 2007-06-30 | AU$0.59 | AU$0.14 | x |
| 2008-06-30 | AU$0.64 | AU$0.14 | x |
| 2009-06-30 | AU$0.39 | AU$0.14 | x |
| 2010-06-30 | AU$0.39 | AU$0.14 | x |
| 2011-06-30 | AU$0.36 | AU$0.14 | x |
| 2012-06-30 | AU$0.38 | AU$0.14 | x |
| 2013-06-30 | AU$0.36 | AU$0.14 | x |
| 2014-06-30 | AU$0.34 | AU$0.14 | x |
| 2015-06-30 | AU$0.37 | AU$0.14 | x |
| 2016-06-30 | AU$0.44 | AU$0.14 | x |
| 2017-06-30 | AU$0.48 | AU$0.14 | x |
| 2018-06-30 | AU$0.55 | AU$0.14 | x |
| 2019-06-30 | AU$0.47 | AU$0.14 | x |
| 2020-06-30 | AU$0.68 | AU$0.14 | x |
| 2021-06-30 | AU$0.24 | AU$0.14 | x |
| 2022-06-30 | AU$0.20 | AU$0.14 | x |
| 2023-06-30 | AU$0.14 | AU$0.14 | x |
| 2024-06-30 | AU$0.10 | AU$0.14 | x |
| 2025-06-30 | AU$0.08 | AU$0.14 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Nova EYE Medical Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -47.76%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -30.95%
- • Asset Turnover: 1.10x
- • Equity Multiplier: 1.40x
- Recent ROE (-47.76%) is below the historical average (-42.05%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1989 | -360.83% | -1168.49% | 0.29x | 1.06x | AU$-13.61 Million |
| 1990 | -295.37% | -387.15% | 0.51x | 1.50x | AU$-2.83 Million |
| 1991 | -29.47% | -95.85% | 0.28x | 1.09x | AU$-432.60K |
| 1992 | -72.20% | -300.56% | 0.21x | 1.14x | AU$-609.10K |
| 1993 | -92.18% | -567.09% | 0.14x | 1.12x | AU$-496.60K |
| 1994 | -73.57% | -176.07% | 0.38x | 1.09x | AU$-234.00K |
| 1995 | 10.38% | 1785.71% | 0.01x | 1.02x | AU$4.60K |
| 1996 | -8.03% | -1828.80% | 0.00x | 1.03x | AU$-309.31K |
| 1997 | -16.39% | -263.73% | 0.06x | 1.06x | AU$-433.15K |
| 1998 | -68.99% | 0.00% | 0.00x | 1.05x | AU$-767.11K |
| 1999 | -140.27% | 0.00% | 0.00x | 1.09x | AU$-779.90K |
| 2000 | -110.46% | 0.00% | 0.00x | 1.60x | AU$-401.32K |
| 2001 | -58.49% | -288750.00% | 0.00x | 1.45x | AU$-540.99K |
| 2002 | -0.54% | -0.61% | 0.71x | 1.26x | AU$-3.25 Million |
| 2003 | 5.34% | 6.29% | 0.70x | 1.21x | AU$-1.43 Million |
| 2004 | -0.68% | -0.84% | 0.64x | 1.26x | AU$-3.25 Million |
| 2005 | -3.80% | -4.09% | 0.69x | 1.35x | AU$-4.00 Million |
| 2006 | 10.51% | 10.65% | 0.75x | 1.32x | AU$178.60K |
| 2007 | 9.86% | 9.38% | 0.71x | 1.47x | AU$-58.90K |
| 2008 | 9.94% | 9.27% | 0.71x | 1.51x | AU$-28.10K |
| 2009 | -75.79% | -38.17% | 1.16x | 1.71x | AU$-25.60 Million |
| 2010 | 11.56% | 7.87% | 0.94x | 1.56x | AU$516.40K |
| 2011 | -2.35% | -1.65% | 0.89x | 1.60x | AU$-3.73 Million |
| 2012 | 2.87% | 1.94% | 1.06x | 1.40x | AU$-2.29 Million |
| 2013 | -2.65% | -1.89% | 0.91x | 1.54x | AU$-3.90 Million |
| 2014 | 2.13% | 1.45% | 1.00x | 1.47x | AU$-2.91 Million |
| 2015 | 4.22% | 2.68% | 1.06x | 1.48x | AU$-2.30 Million |
| 2016 | 6.27% | 4.15% | 1.01x | 1.49x | AU$-1.80 Million |
| 2017 | -1.57% | -1.24% | 0.83x | 1.52x | AU$-6.59 Million |
| 2018 | -6.93% | -6.39% | 0.77x | 1.41x | AU$-12.40 Million |
| 2019 | -9.68% | -41.27% | 0.16x | 1.45x | AU$-13.54 Million |
| 2020 | -6.95% | -54.75% | 0.11x | 1.16x | AU$-17.05 Million |
| 2021 | -12.33% | -32.52% | 0.32x | 1.19x | AU$-7.89 Million |
| 2022 | -24.66% | -56.03% | 0.37x | 1.20x | AU$-10.54 Million |
| 2023 | -65.94% | -89.83% | 0.56x | 1.31x | AU$-17.61 Million |
| 2024 | -41.21% | -37.68% | 0.78x | 1.40x | AU$-10.92 Million |
| 2025 | -47.76% | -30.95% | 1.10x | 1.40x | AU$-10.96 Million |
Industry Comparison
This section compares Nova EYE Medical Ltd's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $14,750,885
- Average return on equity (ROE) among peers: -315.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Nova EYE Medical Ltd (EYE) | AU$15.82 Million | -360.83% | 0.50x | $19.87 Million |
| 4DMEDICAL Ltd (4DX) | $926.64K | -85.93% | 0.18x | $1.03 Billion |
| Adherium Ltd (ADR) | $34.53 Million | -3.63% | 0.08x | $2.37 Million |
| Aroa Biosurgery Ltd (ARX) | $-22.65 Million | 0.00% | 0.00x | $92.74 Million |
| Atomo Diagnostics Ltd (AT1) | $34.48 Million | -26.73% | 0.05x | $8.96 Million |
| Control Bionics Ltd (CBL) | $6.09 Million | -15.97% | 0.04x | $4.98 Million |
| Cardiex Ltd (CDX) | $3.03 Million | -101.61% | 0.73x | $4.25 Million |
| Compumedics Ltd (CMP) | $9.21 Million | -30.70% | 1.16x | $13.08 Million |
| Cochlear Ltd (COH) | $75.42 Million | 53.19% | 1.13x | $7.01 Billion |
| Cleo Diagnostics Ltd (COV) | $5.83 Million | -68.54% | 0.19x | $23.47 Million |
| Conneqt Health Limited (CQT) | $633.50K | -2871.98% | 13.72x | $4.66 Million |